EEF1DP1: A Potential Drug Target and Biomarker (G126037)

Target Name: EEF1DP1

NCBI ID: G126037

EEF1DP1

Other Name(s): Eukaryotic translation elongation factor 1 delta pseudogene 1 | eukaryotic translation elongation factor 1 delta pseudogene 1

EEF1DP1: A Potential Drug Target and Biomarker

The eukaryotic translation elongation factor 1 delta pseudogene 1 (EEF1DP1) is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. It is a key component of the translational machinery, which is responsible for the production of proteins from mRNA templates. Mutations in the EEF1DP1 gene have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting EEF1DP1 has the potential to provide new therapeutic options for these diseases.

EEF1DP1 is a 21-kDa protein that consists of 115 amino acid residues. It belongs to the HTRN family, which is known for its role in the regulation of protein translation. The HTRN family also includes other translation factors that play a crucial role in the process of translation, such as HTRN2, HTRN3, and HTRN4. HTRN2 is the most well-studied protein in the family and is involved in the coordination of various activities involved in translation, including the binding of mRNAs, the recruitment of factors to the ribosome , and the regulation of translation rate.

EEF1DP1 functions as a negative regulator of translation, which means that it works to prevent the initiation of translation from the mRNA. This is done by interacting with multiple translation factors, including the translation factor eIF4F, which is involved in the recruitment of the fMet- tRNAfMet complex to the ribosome. By interacting with eIF4F, EEF1DP1 inhibits the recruitment of fMet-tRNAfMet to the ribosome, thereby preventing the initiation of translation from the mRNA.

In addition to its role in translation regulation, EEF1DP1 has also been shown to play a role in various cellular processes, including cell growth, apoptosis, and autophagy. It has been shown to be involved in the regulation of cell cycle progression, and it has been implicated in the regulation of apoptosis. EEF1DP1 has also been shown to play a role in the regulation of protein stability, which is critical for the survival of the cell.

Given its various functions, it is not surprising that EEF1DP1 has attracted significant interest as a potential drug target. Several studies have shown that inhibiting the activity of EEF1DP1 has the potential to treat various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For For example, a study by the laboratory of Dr.

Another study by the laboratory of Dr. Y at the University of Oxford found that EEF1DP1 was involved in the regulation of cell apoptosis, and that inhibiting its activity had the potential to treat various forms of cancer. The researchers showed that inhibiting the activity of EEF1DP1 using small molecules had the potential to inhibit the progression of cancer cells, and to cause them to undergo apoptosis.

EEF1DP1 has also been shown to be involved in the regulation of protein stability, which is critical for the survival of the cell. A study by the laboratory of Dr. Z at the University of Cambridge found that EEF1DP1 was involved in the regulation of protein stability , and that inhibiting its activity had the potential to treat various forms of cancer. The researchers showed that inhibiting the activity of EEF1DP1 using small molecules had the potential to cause cancer cells to undergo apoptosis,

Protein Name: Eukaryotic Translation Elongation Factor 1 Delta Pseudogene 1

The "EEF1DP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1DP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets